<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638063</url>
  </required_header>
  <id_info>
    <org_study_id>GuangzhouIRD01</org_study_id>
    <nct_id>NCT03638063</nct_id>
  </id_info>
  <brief_title>ATP and Capsaicin Cough Provocation Test in Chronic Cough and Bronchiectasis</brief_title>
  <official_title>Adenosine Triphosphate and Capsaicin Cough Provocation Test for Identifing Patients With Chronic Cough Who Have Differential Responses to Purinergic Receptor Antagonists: a Randomized, Cross-over, Single-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, cross-over, single-blind trial. Eligible patients will be randomly
      assigned to undergo either capsaicin or adenosine triphosphate (ATP) cough provocation test,
      followed by a washout period of 2 to 14 days. Participants will be crossed-over to undergo
      another cough provocation test. Patient would be under observation in the out-patient clinics
      for ~2 hours following the cough provocation tests in case of severe adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, cross-over, single-blind trial. After verification of the entry
      criteria, eligible patients will be, based on the randomization codes, randomly assigned to
      undergo either capsaicin or ATP cough provocation test (the participants will inhale
      capasaicin or ATP incremental concentration to induce cough, meanwhile the number of coughs
      and adverse events will be recorded in each concentration during the first 30 seconds),
      followed by a washout period of 2 to 14 days (no major changes in the use of concomitant
      medications are allowed,especially the medcines which are not allowed before test ).
      Participants will be crossed-over to undergo another cough provocation test. Patient would be
      under observation in the out-patient clinics for ~2 hours following the cough provocation
      tests in case of severe adverse events. Twenty four hours after each test, a follow-up
      telephone visit will be scheduled for all patients to record any response which may be
      related to the test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>C5 (Provocant concentration eliciting at least 5 coughs)</measure>
    <time_frame>18 months</time_frame>
    <description>Provocant concentration eliciting at least 5 coughs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ED50 (half maximal effective Dose)</measure>
    <time_frame>18 months</time_frame>
    <description>50% effective dose of provocant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emax (effective concentration of provocant eliciting maximal cough count)</measure>
    <time_frame>18 months</time_frame>
    <description>effective concentration of provocant eliciting maximal cough count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potency ratio</measure>
    <time_frame>18 months</time_frame>
    <description>ATP/capsaicin potency ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in cough VAS score (a 10-point likert scale for assessing the global severity of cough, no subscale was applied)</measure>
    <time_frame>18 months</time_frame>
    <description>The difference between pre- and post-challenge cough VAS scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events (i.e. dry throat , pharyngeal itching)</measure>
    <time_frame>18 months</time_frame>
    <description>adverse events such as dry throat , pharyngeal itching, wheeze or dyspnea according to the subject's reporting to record the rate of the incidence and the severity (the aboved-mentioned VAS score would be applied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough dose ratio (CDR)</measure>
    <time_frame>18 months</time_frame>
    <description>the ratio of cough count and dose/concentration</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Cough</condition>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Chronic cough</arm_group_label>
    <description>patients with chronic cough who remain clinically stable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bx</arm_group_label>
    <description>bronchiectasis patients who remain clinically stable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Adenosine Triphosphate</intervention_name>
    <description>Adenosine Triphosphate aerosol</description>
    <arm_group_label>Bx</arm_group_label>
    <arm_group_label>Chronic cough</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>capsaicin</intervention_name>
    <description>capsaicin aerosol</description>
    <arm_group_label>Bx</arm_group_label>
    <arm_group_label>Chronic cough</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with chronic cough (including bronchiectasis) who remained clinically stable for
        at least 4 weeks
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out-patients of either gender, ex- or never-smokers, aged between 18 and 60 years

          -  Cough symptoms lasting for more than 8 weeks

          -  Remaining free of acute upper respiratory tract infection for at least 4 weeks

          -  Agreed to participate in the trial and signed informed consent.

        Exclusion Criteria:

          -  Patients with serious systemic diseases (such as malignant tumors), bullae, severe
             uncontrolled asthma, and a history of major hemoptysis

          -  Systemic antibiotic use (except for maintenance low-dose macrolides) within 4 weeks

          -  Pregnancy or lactation

          -  Any known history of sensitivity to ATP or capsaicin

          -  Poor understanding of the test procedure

          -  Diagnosed with cough variant asthma or Eosinophilic bronchitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ke-fang Lai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangzhou Institute of Respiratory Health Locations: China, Guangdong First Affiliated Hospital of Guangzhou Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei-jie Guan, MD</last_name>
    <phone>+86-13826042052</phone>
    <email>battery203@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing jing Yuan, Msc</last_name>
    <phone>+86-13502414649</phone>
    <email>jacyyjj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-jie Guan</last_name>
      <email>battery203@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ke-fang Lai</last_name>
      <email>klai@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fowles HE, Rowland T, Wright C, Morice A. Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity? Eur Respir J. 2017 Feb 8;49(2). pii: 1601452. doi: 10.1183/13993003.01452-2016. Print 2017 Feb.</citation>
    <PMID>28179439</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, Lin ZM, Zheng JP, Chen RC, Zhong NS. Capsaicin cough sensitivity and the association with clinical parameters in bronchiectasis. PLoS One. 2014 Nov 19;9(11):e113057. doi: 10.1371/journal.pone.0113057. eCollection 2014.</citation>
    <PMID>25409316</PMID>
  </reference>
  <reference>
    <citation>Torrego A, Haque RA, Nguyen LT, Hew M, Carr DH, Wilson R, Chung KF. Capsaicin cough sensitivity in bronchiectasis. Thorax. 2006 Aug;61(8):706-9. Epub 2006 Apr 6.</citation>
    <PMID>16601085</PMID>
  </reference>
  <reference>
    <citation>Fuller RW. Cough provocation tests: their clinical value. Pulm Pharmacol Ther. 2002;15(3):273-6. Review.</citation>
    <PMID>12099777</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>February 8, 2020</last_update_submitted>
  <last_update_submitted_qc>February 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>Weijie Guan</investigator_full_name>
    <investigator_title>Associated professor; principal investigator (respiratory medicine)</investigator_title>
  </responsible_party>
  <keyword>Adenosine triphosphate</keyword>
  <keyword>Capsaicin</keyword>
  <keyword>cough provocation test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

